更正：单独使用罗伊氏乳杆菌ATCC PTA 6475以及联合罗伊氏乳杆菌DSM 17938进行为期6周的干预对腹泻型肠易激综合征患者肠道屏障功能、免疫标志物及症状的影响——一项探索性随机对照试验
Correction: The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
出版信息
PLoS One. 2025 Feb 21;20(2):e0316404. doi: 10.1371/journal.pone.0316404. eCollection 2025.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0312464.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0312464。]
相似文献
1
Correction: The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
PLoS One. 2025 Feb 21;20(2):e0316404. doi: 10.1371/journal.pone.0316404. eCollection 2025.
2
The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
PLoS One. 2024 Nov 1;19(11):e0312464. doi: 10.1371/journal.pone.0312464. eCollection 2024.
3
ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial.
Benef Microbes. 2021 Apr 12;12(2):137-145. doi: 10.3920/BM2020.0171. Epub 2021 Apr 1.
4
Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659.
J Ind Microbiol Biotechnol. 2023 Feb 17;50(1). doi: 10.1093/jimb/kuad041.
5
Effects of Limosilactobacillus reuteri strains PTA-126787 and PTA-126788 on intestinal barrier integrity and immune homeostasis in an alcohol-induced leaky gut model.
Sci Rep. 2024 Aug 23;14(1):19584. doi: 10.1038/s41598-024-70549-6.
6
Orodispersible lozenges containing a combination of DSM 17938 and ATCC PTA 5289 and normal gum function: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.
EFSA J. 2020 Mar 6;18(3):e06004. doi: 10.2903/j.efsa.2020.6004. eCollection 2020 Mar.
7
In silico, in vitro and in vivo safety evaluation of Limosilactobacillus reuteri strains ATCC PTA-126787 & ATCC PTA-126788 for potential probiotic applications.
PLoS One. 2022 Jan 26;17(1):e0262663. doi: 10.1371/journal.pone.0262663. eCollection 2022.
8
sp. nov., sp. nov., sp. nov., sp. nov. and sp. nov., five novel species isolated from the vertebrate gastrointestinal tract, and proposal of six subspecies of adapted to the gastrointestinal tract of specific vertebrate hosts.
Int J Syst Evol Microbiol. 2021 Feb;71(2). doi: 10.1099/ijsem.0.004644.
9
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis.
Sci Rep. 2020 Oct 1;10(1):16189. doi: 10.1038/s41598-020-73292-w.
10
Genome-scale insights into the metabolic versatility of Limosilactobacillus reuteri.
BMC Biotechnol. 2021 Jul 30;21(1):46. doi: 10.1186/s12896-021-00702-w.
本文引用的文献
1
The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
PLoS One. 2024 Nov 1;19(11):e0312464. doi: 10.1371/journal.pone.0312464. eCollection 2024.
Zotero 插件